Maryam Oroujeni
Postdoktor vid Institutionen för immunologi, genetik och patologi; Forskningsprogram: Cancerprecisionsmedicin; Forskargrupp Vladimir Tolmachev
- E-post:
- maryam.oroujeni@igp.uu.se
- Besöksadress:
- Dag Hammarskjölds väg 20
751 85 Uppsala - Postadress:
- Rudbecklaboratoriet
751 85 UPPSALA
Mer information visas för dig som medarbetare om du loggar in.
Publikationer
Senaste publikationer
- Reduction of renal activity retention of radiolabeled albumin binding domain-derived affinity proteins using a non-residualizing label strategy compared with a cleavable glycine-leucine-glycine-lysine-linker (2024)
- 177Lu-labeled PSMA targeting therapeutic with optimized linker for treatment of disseminated prostate cancer; evaluation of biodistribution and dosimetry (2023)
- Preclinical Evaluation of a Novel High-Affinity Radioligand [99mTc]Tc-BQ0413 Targeting Prostate-Specific Membrane Antigen (PSMA) (2023)
- Phase I clinical evaluation of 99mTc-labeled Affibody molecule for imaging HER2 expression in breast cancer (2023)
- Conditionally activated affibody-based prodrug targeting EGFR demonstrates improved tumour selectivity (2023)
Alla publikationer
Artiklar
- Reduction of renal activity retention of radiolabeled albumin binding domain-derived affinity proteins using a non-residualizing label strategy compared with a cleavable glycine-leucine-glycine-lysine-linker (2024)
- 177Lu-labeled PSMA targeting therapeutic with optimized linker for treatment of disseminated prostate cancer; evaluation of biodistribution and dosimetry (2023)
- Preclinical Evaluation of a Novel High-Affinity Radioligand [99mTc]Tc-BQ0413 Targeting Prostate-Specific Membrane Antigen (PSMA) (2023)
- Phase I clinical evaluation of 99mTc-labeled Affibody molecule for imaging HER2 expression in breast cancer (2023)
- Conditionally activated affibody-based prodrug targeting EGFR demonstrates improved tumour selectivity (2023)
- Evaluation of affinity matured Affibody molecules for imaging of the immune checkpoint protein B7-H3 (2023)
- Comparison of HER2-targeted affibody conjugates loaded with auristatin-and maytansine-derived drugs (2023)
- Preclinical Evaluation of a New Format of Ga-68- and In-111-Labeled Affibody Molecule Z(IGF-1R:4551) for the Visualization of IGF-1R Expression in Malignant Tumors Using PET and SPECT (2022)
- Evaluation of an Affibody-Based Binder for Imaging of Immune Check-Point Molecule B7-H3 (2022)
- Affibody-Mediated PNA-Based Pretargeted Cotreatment Improves Survival of Trastuzumab-Treated Mice Bearing HER2-Expressing Xenografts (2022)
- Direct In Vivo Comparison of 99mTc-Labeled Scaffold Proteins, DARPin G3 and ADAPT6, for Visualization of HER2 Expression and Monitoring of Early Response for Trastuzumab Therapy (2022)
- Effect of Inter-Domain Linker Composition on Biodistribution of ABD-Fused Affibody-Drug Conjugates Targeting HER2 (2022)
- Affibody-Derived Drug Conjugates Targeting HER2 (2021)
- Targeting HER2 Expressing Tumors with a Potent Drug Conjugate Based on an Albumin Binding Domain-Derived Affinity Protein (2021)
- Radionuclide therapy using ABD-fused ADAPT scaffold protein (2021)
- Preclinical Evaluation of Tc-99m-ZHER2:41071, a Second-Generation Affibody-Based HER2-Visualizing Imaging Probe with a Low Renal Uptake (2021)
- The Use of a Non-Conventional Long-Lived Gallium Radioisotope 66Ga Improves Imaging Contrast of EGFR Expression in Malignant Tumours Using DFO-ZEGFR (2021)
- Comparative Evaluation of Novel Lu-177-Labeled PNA Probes for Affibody-Mediated PNA-Based Pretargeting (2021)
- Drug Conjugates Based on a Monovalent Affibody Targeting Vector Can Efficiently Eradicate HER2 Positive Human Tumors in an Experimental Mouse Model (2021)
- The Influence of Domain Permutations of an Albumin-Binding Domain-Fused HER2-Targeting Affibody-Based Drug Conjugate on Tumor Cell Proliferation and Therapy Efficacy (2021)
- Investigation of a Pharmacological Approach for Reduction of Renal Uptake of Radiolabeled ADAPT Scaffold Protein (2020)
- Comparative evaluation of dimeric and monomeric forms of ADAPT scaffold protein for targeting of HER2-expressing tumours (2019)
- Evaluation of Tumor-Targeting Properties of an Antagonistic Bombesin Analogue RM26 Conjugated with a Non-Residualizing Radioiodine Label Comparison with a Radiometal-Labelled Counterpart (2019)
- Selection of the optimal macrocyclic chelators for labeling with 111In and 68Ga improves contrast of HER2 imaging using engineered scaffold protein ADAPT6 (2019)
- Selection of the most optimal ADAPT6-based probe for imaging of HER2 using PET and SPECT (2018)
- Optimized Molecular Design of ADAPT-Based HER2-Imaging Probes Labeled with 111In and 68Ga (2018)
- Influence of composition of cysteine-containing peptide-based chelators on biodistribution of 99mTc-labeled anti-EGFR affibody molecules (2018)
- Comparative evaluation of anti-EFGR affibody molecules labelled with gallium-68 and zirconium-89 using desferrioxamine B as a chelator (2018)
- Preclinical Evaluation of [Ga-68]Ga-DFO-ZEGFR:2377 (2018)
- Conjugation of cyclodextrin to magnetic Fe3O4 nanoparticles via polydopamine coating for drug delivery (2018)
- PP15 89Zr-Siderophore-Affibody conjugates for imaging EGFR expression (2018)
- Cyclic versus Noncyclic Chelating Scaffold for Zr-89-Labeled ZEGFR:2377 Affibody Bioconjugates Targeting Epidermal Growth Factor Receptor Overexpression (2018)
- Radionuclide Therapy of HER2-Expressing Human Xenografts Using Affibody-Based Peptide Nucleic Acid-Mediated Pretargeting (2018)
- Influence of composition of cysteine-containing peptide based chelators on biodistribution of Tc-99m-labelled anti-EGFR affibody molecules (2017)
- Feasibility of imaging of epidermal growth factor receptor expression with ZEGFR (2016)
- Imaging of EGFR Expression Using 99mTC-Labelled ZEGFR:2377 Affibody Molecule (2016)
Böcker
